New drug combo shows promise for hard-to-treat thyroid cancer
NCT ID NCT04061980
First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tests whether a two-drug targeted therapy (encorafenib and binimetinib) works better with or without the immunotherapy drug nivolumab for people with a specific type of advanced thyroid cancer (BRAF V600 mutant) that has spread and no longer responds to standard radioactive iodine treatment. About 24 participants will receive either the two-drug combo alone or the two drugs plus nivolumab. The goal is to see if adding immunotherapy improves tumor shrinkage and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.